PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) management announced today that the company has no plans for a reverse split of the company's outstanding shares of common stock, currently or in the foreseeable future. Management noted that reverse splits are often detrimental to shareholder value and stated that the company is therefore not considering such an action to effect a rise in the current price per share of the company's stock, though management believes the price per share to be undervalued and not representative of the company's inherent value and prospects of future growth and earnings.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. (PHMB) has positioned itself to become a leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management specializes in Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that enable animals suffering from cancer potentially greater life expectancy and decreased suffering. To learn more, please go to the Corporations Web site www.pharmacombiovet.com.

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Contact: PharmaCom BioVet, Inc. Investor Relations Tel: 919-604-4887 URL: http://www.PharmaComBioVet.com